<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NORITATE - metronidazole cream </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First">FOR TOPICAL USE ONLY<br>(NOT FOR OPHTHALMIC USE)</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"></p>
<p><span class="Bold">NORITATE
</span>(metronidazole
cream) <span class="Bold">Cream,
1%, </span>contains
metronidazole, USP.  Chemically, metronidazole is
2-methyl-5-nitro-1<span class="Italics">H</span>-imidazole-1-ethanol.
The molecular formula for metronidazole is C6H9N3O3.
It has the following structural formula:</p>
<p><img alt="image of chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1787c491-d92c-4239-9d9f-6a91b629835d&amp;name=chemical%20structure.jpg"></p>
<p>Metronidazole
has a molecular weight of 171.16. It is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow
crystalline powder. It is slightly soluble in alcohol and has a
solubility in water of 10 mg/mL at 20°C. Metronidazole is a member
of the imidazole class of antibacterial agents and is classified as
an antiprotozoal and anti-bacterial agent.</p>
<p><span class="Bold">NORITATE
</span>is an emollient cream; each gram contains 10
mg micronized metronidazole USP, in a base of purified water USP,
stearic acid NF, glyceryl monostearate NF, glycerin USP,
methylparaben NF, trolamine NF and propylparaben NF.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<p><span class="Bold">Pharmacokinetics:
</span></p>
<p>When
one gram dose of <span class="Bold">NORITATE </span>cream,
1%, was applied in a single application to the face of 16 healthy
volunteers, low concentrations of metronidazole were detected in the
plasma of 7 of the volunteers. The mean ± SD Cmax
of metronidazole was 27.6 ± 7.3 ng/mL, which is
about 1% of the value reported for a single 250 mg oral dose of
metronidazole. The time to maximum plasma concentration (Tmax)
in the volunteers with detectable metronidazole was 8-12 hoursafter
topical application.<br><br></p>
<p><span class="Bold">Pharmacodynamics:
</span></p>
<p>The
mechanisms by which metronidazole acts in reducing inflammatory
lesions of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> are unknown.</p>
<p><span class="Bold">Clinical
Studies: </span></p>
<p>Safety
and efficacy of <span class="Bold">NORITATE </span>were
evaluated in two randomized vehicle-controlled clinical studies for
the treatment of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span>, which excluded patients who had <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span>,
moderate or severe rhinophyma, dense telangiectases, plaque-like
facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or ocular involvement and those who had a history of not
responding to metronidazole therapy for <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span>. Of the patients</p>
<p>included
in the efficacy database (n=416), there were 142 men and 274 women. 
Endpoint efficacy data comparisons for patients treated
with daily <span class="Bold">NORITATE
</span>or
vehicle applications are listed below.</p>
<a name="ic5fd9300-8e30-48a4-8ef2-a15191026a36"></a><table width="80%">
<caption><span>Inflammatory Lesion Counts and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span> Severity Scores in Two Clinical Trials for <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">Rosacea</span></span></caption>
<tbody class="Headless">
<tr class="First">
<td><br></td>
<td><br></td>
<td><span class="Bold">Nori</span></td>
<td>t<span class="Bold">ate</span>
</td>
<td><br></td>
<td><br></td>
<td>
<span class="Bold">V</span><span class="Bold">ehi</span>
</td>
<td><span class="Bold">cle</span></td>
<td><br></td>
</tr>
<tr>
<td><br></td>
<td><span class="Bold">Study</span></td>
<td><span class="Bold">1</span></td>
<td><span class="Bold">Study</span></td>
<td><span class="Bold">2</span></td>
<td><span class="Bold">Study</span></td>
<td><span class="Bold">1</span></td>
<td><span class="Bold">Study</span></td>
<td><span class="Bold">2</span></td>
</tr>
<tr>
<td><br></td>
<td>N<br>
</td>
<td>Result<br>
</td>
<td>N<br>
</td>
<td>Result<br>
</td>
<td>N<br>
</td>
<td>Result<br>
</td>
<td>N<br>
</td>
<td>Result<br>
</td>
</tr>
<tr>
<td>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">Papules</span> + <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">Pustules</span> Count</span><br>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>Baseline<br>
</td>
<td>89<br>
</td>
<td>15<br>
</td>
<td>92<br>
</td>
<td>19<br>
</td>
<td>50<br>
</td>
<td>18<br>
</td>
<td>49<br>
</td>
<td>17<br>
</td>
</tr>
<tr>
<td>Week-10<br>
</td>
<td>80<br>
</td>
<td>7*<br>
</td>
<td>82<br>
</td>
<td>8<br>
</td>
<td>45<br>
</td>
<td>15<br>
</td>
<td>41<br>
</td>
<td>12<br>
</td>
</tr>
<tr>
<td>   Reduction<br>
</td>
<td><br></td>
<td>49%*<br>
</td>
<td><br></td>
<td>58%*<br>
</td>
<td><br></td>
<td>17%<br>
</td>
<td><br></td>
<td>30%<br>
</td>
</tr>
<tr>
<td>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">Papules</span> Count</span><br>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>Baseline<br>
</td>
<td>89<br>
</td>
<td>13<br>
</td>
<td>92<br>
</td>
<td>17<br>
</td>
<td>50<br>
</td>
<td>15<br>
</td>
<td>49<br>
</td>
<td>15<br>
</td>
</tr>
<tr>
<td>Week-10<br>
</td>
<td>80<br>
</td>
<td>7*<br>
</td>
<td>82<br>
</td>
<td>7<br>
</td>
<td>45<br>
</td>
<td>12<br>
</td>
<td>41<br>
</td>
<td>11<br>
</td>
</tr>
<tr>
<td>   Reduction<br>
</td>
<td><br></td>
<td>41%*<br>
</td>
<td><br></td>
<td>55%*<br>
</td>
<td><br></td>
<td>14%<br>
</td>
<td><br></td>
<td>28%<br>
</td>
</tr>
<tr>
<td>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span> Score</span><br>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>Baseline<br>
</td>
<td>89<br>
</td>
<td>2.2<br>
</td>
<td>92<br>
</td>
<td>2.3<br>
</td>
<td>50<br>
</td>
<td>2.2<br>
</td>
<td>49<br>
</td>
<td>2.2<br>
</td>
</tr>
<tr>
<td>Week-10<br>
</td>
<td>80<br>
</td>
<td>1.3*<br>
</td>
<td>82<br>
</td>
<td>1.4*<br>
</td>
<td>45<br>
</td>
<td>1.7<br>
</td>
<td>40<br>
</td>
<td>1.8<br>
</td>
</tr>
<tr class="Last">
<td>   Reduction<br>
</td>
<td><br></td>
<td>42%*<br>
</td>
<td><br></td>
<td>40%*<br>
</td>
<td><br></td>
<td>25%<br>
</td>
<td><br></td>
<td>19%<br>
</td>
</tr>
</tbody>
</table>* Statistically significant differences between NORITATE and vehicle groups with p<span class="Underline">&lt;</span>0.05. <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span> scores: 0=none, 1=mild, 2=moderate and 3=severe.<br><br>Safety Studies: <br><br>Studies of contact sensitization (n=258), <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> (n=21), and photocontact sensitization (n=29) of NORITATE were conducted. No evidence of sensitization or <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> was seen in these studies.<p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"></p>
<p><span class="Bold">NORITATE
</span>is indicated for the topical treatment of
inflammatory lesions and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"></p>
<p><span class="Bold">NORITATE
</span>is contraindicated in those patients with a
history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to metronidazole or to any other
ingredient in this formulation.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"></p>
<p><span class="Bold">General:
</span></p>
<p>If
a reaction suggesting local <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span> occurs, patients should
be directed to discontinue use of the medication. <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>
associated with topical use of metronidazole on the face has been
reported. Contact with the eyes should be avoided. Metronidazole is a
nitroimidazole and should be used with care in patients with evidence
of, or history of, <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasia</span>.</p>
<p><span class="Bold"><br></span></p>
<p><span class="Bold">Information
for Patients: </span></p>
<p>Patients
using <span class="Bold">NORITATE </span>should
receive the following information and instructions:</p>
<p>1.
This medication is to be used as directed.</p>
<p>2.
It is for external use only.</p>
<p>3.
Avoid contact with the eyes.</p>
<p>4.
Cleanse affected area(s) before applying <span class="Bold">NORITATE</span>.</p>
<p>5.
This medication should not be used for any disorder other than that
for which it is prescribed. </p>
<p>6.
Patients should report any adverse reaction to their physician.</p>
<p><span class="Bold"><br></span></p>
<p><span class="Bold">Drug
Interactions: </span></p>
<p>Oral
metronidazole has been reported to potentiate the anticoagulant
effect of coumarin and warfarin resulting in a prolongation of
<span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. Drug interactions should be kept in mind when
<span class="Bold">NORITATE </span>is prescribed
for patients who are receiving anticoagulant treatment, although they
are less likely to occur with topical metronidazole administration
because of low absorption. (See <span class="Bold">CLINICAL
PHARMACOLOGY, Pharmacokinetics </span>section) </p>
<p><br></p>
<p><span class="Bold">Carcinogenesis,
Mutagenesis and Impairment of Fertility:</span></p>
<p>Metronidazole
has shown evidence of carcinogenic activity in a number of studies
involving chronic, oral administration in mice and rats but not in
studies involving hamsters. In several long term studies in mice,
oral doses of approximately 225 mg/m2/day
or greater (approximately 37 times the human topical dose on a mg/m2
basis) were associated with an increase in
pulmonary tumors and <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span>. Several long term oral studies in the
rat have shown statistically significant increases in mammary and
hepatic tumors at doses &gt;885 mg/m2/day
(144 times the topical human dose). </p>
<p>Metronidazole
has shown evidence of mutagenic activity in several <span class="Italics">in
vitro </span>bacterial assay systems. In addition, a
dose-related increase in the frequency of micronuclei was observed in
mice after intraperitoneal injections. An increase in chromosomal
aberrations in peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> was reported in patients
with Crohn’s disease who were treated with 200 to 1200 mg/day of
metronidazole for 1 to 24 months. However, in another study, no
increase in chromosomal aberrations in circulating <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> was
observed in patients with Crohn’s disease treated with the drug for
8 months.</p>
<p>In
one published study, using albino hairless mice, intraperitoneal
administration of metronidazole at a dose of 45 mg/m2/day
(approximately 7 times the human topical dose on a mg/m2
basis) was associated with an increase in ultraviolet
radiationinduced skin carcinogenesis. Neither dermal carcinogenicity
nor photocarcinogenicity studies have been performed with <span class="Bold">NORITATE
</span>or any marketed metronidazole<br>formulations.</p>
<p><span class="Bold">Pregnancy:
</span></p>
<p><span class="Italics">Teratogenic
Effects: </span>Pregnancy Category B. There are no
adequate and well controlled studies with the use of <span class="Bold">NORITATE
</span>in pregnant women. Metronidazole crosses the
placental barrier and enters the fetal circulation rapidly. No
fetotoxicity was observed after oral administration of metronidazole
to rats or mice at 200 and 20 times, respectively, the expected
clinical dose. However, oral metronidazole has shown carcinogenic
activity in rodents. Because animal reproduction studies are not
always predictive of human response, <span class="Bold">NORITATE
</span>should be used during pregnancy only if
clearly needed.</p>
<p><span class="Bold"><br></span></p>
<p><span class="Bold">Nursing
Mothers: </span></p>
<p>After
oral administration, metronidazole is secreted in breast milk in
concentrations similar to those found in the plasma. Even though
blood levels taken after topical metronidazole application are
significantly lower than those achieved after oral metronidazole, a
decision should be made whether to discontinue the mother and the
risk to the infant.</p>
<br><p><span class="Bold">Pediatric
Use: </span></p>
<p>Safety
and effectiveness in pediatric patients have not been established.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"></p>
<p>Safety
data from 302 patients who used <span class="Bold">NORITATE
</span>(n=200) or vehicle control (n=102) once daily
in clinical trials and experienced an adverse event considered to be
treatment-related include: <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reaction</span> (<span class="Bold">NORITATE
</span>1, vehicle 1), condition aggravated (<span class="Bold">NORITATE
</span>1, vehicle 0), <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> (<span class="Bold">NORITATE
</span>0, vehicle 1), <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> (<span class="Bold">NORITATE
</span>1, vehicle 0), <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span> (<span class="Bold">NORITATE
</span>0, vehicle 2). The majority
of adverse reactions were mild to moderate in severity.</p>
<p></p>
<p>Two
patients treated with <span class="Bold">NORITATE </span>once
daily discontinued treatment because of adverse events: one for a
severe flare of comedonal <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> and one for <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> aggravated.</p>
<p>Additional
clinical adverse effects reported spontaneously since the drug was
marketed are uncommon and include <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> of
extremities, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, skin and <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>,
<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"></p>
<p>Areas
to be treated should be cleansed before application of <span class="Bold">NORITATE</span>.
Apply and rub in a thin film of <span class="Bold">NORITATE </span>once
daily to entire affected area(s). Patients may use cosmetics after
application of <span class="Bold">NORITATE</span>.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"></p>
<p>Cream
- 60 gram aluminum tube NDC 54868-4449-1.</p>
<p><br></p>
<p>Keep
out of the reach of children.</p>
<p><br></p>
<p><span class="Bold">Storage
Conditions: </span>Store at controlled room
temperature: 20 to 25°C (68 to 77°F).</p>
<p><br></p>
<p><br></p>
<p><span class="Bold">Rx
Only</span></p>
<p><span class="Bold">Dermik
Laboratories</span></p>
<p>a
business of sanofi-aventis U.S. LLC</p>
<p>Bridgewater,
NJ 08807</p>
<p>Revised
December 2006</p>
<p>©
2006
sanofi-aventis U.S. LLC</p>
<p><br></p>
<p><span class="Bold">Relabeling of "Additional" label by:</span><br>Physicians Total Care, Inc.<br>Tulsa, OK     74146<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-10"></a><p></p>
<h1>PACKAGE LABEL PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">Noritate (metronidazole cream) Cream, 1%</span></p>
<p>60 gram</p>
<p>NDC 54868-4449-1</p>
<p><img alt="image of 60 gram package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1787c491-d92c-4239-9d9f-6a91b629835d&amp;name=4449.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NORITATE 		
					</strong><br><span class="contentTableReg">metronidazole cream</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4449(NDC:0066-9850)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METRONIDAZOLE</strong> (METRONIDAZOLE) </td>
<td class="formItem">METRONIDAZOLE</td>
<td class="formItem">10 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERYL MONOSTEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TROLAMINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4449-1</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020743</td>
<td class="formItem">09/29/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>91407a94-b1c0-4ff9-a132-1c5168a2f4e2</div>
<div>Set id: 1787c491-d92c-4239-9d9f-6a91b629835d</div>
<div>Version: 1</div>
<div>Effective Time: 20110506</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
